Human islet transplantation: Lessons from 13 autologous and 13 allogeneic transplantations

Transplantation

Volumn 69, Issue 6, 2000, Pages 1115-1123

  Oberholzer, José ^a,b   Triponez, Frédéric ^a   Mage, Raymond ^a   Andereggen, Elisabeth ^a   Bühler, Léo ^a   Crétin, Nathalie ^a   Fournier, Béatrice ^a   Goumaz, Claudine ^a   Lou, Jinning ^c   Philippe, Jacques ^a   Morel, Philippe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CYTOTOXICITY TEST; HUMAN; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTOTOXICITY; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PANCREAS TUMOR; PRIORITY JOURNAL;

EID: 17944397893     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003270-00016     Document Type: Article

References (38)

1. Weir GC, Bonner-Weir S. Scientific and political impediments to successful islet transplantation. Diabetes 1997; 46(8): 1247.
2. National Diabetes Fact Sheet: National estimates and general information on diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1997.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977.
4. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341(8856): 1306.
5. Gautier JF, Beressi JP, Leblanc H, Vexiau P, Passa P. Are the implications of the Diabetes Control and Complications Trial (DCCT) feasible in daily clinical practice? Diabetes Metab 1996; 22(6): 415.
6. Morel P, Chau C, Brayman K, et al. Quality of metabolic control at 2 to 12 years after a pancreas transplant. Transplant Proc 1992; 24(3): 835.
7. Gruessner AC, Sutherland DE, Gruessner RW. Report of the International Pancreas Transplant Registry. Transplant Proc 1998; 30(2): 242.
8. Landgraf R. Impact of pancreas transplantation on diabetic secondary complications and quality of life. Diabetologia 1996; 39(12): 1415.
9. Meyer C, Hering BJ, Grossmann R, et al. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation 1998; 66(2): 233.
10. Wahoff DC, Papalois BE, Najarian JS, et al. Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg 1995; 222(4): 562.
11. Robertson GS, Dennison AR, Johnson PR, London NJ. A review of pancreatic islet autotransplantation. Hepatogastroenterology 1998; 45(19): 226.
12. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998; 47(3): 324.
13. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37(4): 413.
14. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27(3): 185.
15. Janjic D, Andereggen E, Deng S, et al. Improved insulin secretion of cryopreserved human islets by antioxidant treatment. Pancreas 1996; 13(2): 166.
16. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350(9086): 1193.
17. Hering BJ, Bretzel RG, Hopt UT, et al. New protocol toward prevention of early human islet allograft failure. Transplant Proc 1994; 26(2): 570.
18. Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999; 77(1): 140.
19. Vartdal F, Gaudernack G, Funderud S, et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation: a fast and reliable technique. Tissue Antigens 1986; 28(5): 301.
20. Farney AC, Hering BJ, Nelson L, et al. No late failures of intraportal human islet autografts beyond 2 years. Transplant Proc 1998; 30(2): 420.
21. Lou J, Triponez F, Oberholzer J, et al. Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. Diabetes 1999; 48(9): 1773.
22. Cepinskas G, Noseworthy R, Kvietys PR. Transendothelial neutrophil migration: role of neutrophil-derived proteases and relationship to transendothelial protein movement. Circ Res 1997; 81(4): 618.
23. Vajkoczy P, Olofsson AM, Lehr HA, et al. Histogenesis and ultrastructure of pancreatic islet graft microvasculature: evidence for graft revascularization by endothelial cells of host origin. Am J Pathol 1995; 146(6): 1397.
24. Keymeulen B, Ling Z, Gorus F, et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998; 41: 452.
25. Jindal RM, Fineberg SE, Sherman S, et al. Clinical experience with autologous and allogeneic pancreatic islet transplantation. Transplantation 1998; 66(12): 1836.
26. Benhamou PY, Watt PC, Mullen Y, et al. Human islet isolation in 104 consecutive cases: factors affecting isolation success. Transplantation 1994; 57(12): 1804.
27. Brandhorst D, Brandhorst H, Hering BJ, Federlin K, Bretzel RG. Islet isolation from the pancreas of large mammals and humans: 10 years of experience. Exp Clin Endocrinol Diabetes 1995; 103 (suppl 2): 3.
28. Rosenberg L. Clinical islet cell transplantation. Are we there yet? Int J Pancreatol 1998; 24(3): 145.
29. Hering BJ, Ricordi C. Islet transplantation for patients with type 1 diabetes. Graft 1999; 2(1): 12.
30. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999; 48(3): 484.
31. Olack BJ, Swanson CJ, Flavin KS, et al. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc 1997; 29(4): 2268.
32. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335(12): 860.
33. Bosi E, Bottazzo GF, Secchi A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes 1989; 38 (suppl 1): 82.
34. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997; 46(11): 1907.
35. Petersen JS, Kulmala P, Clausen JT, Knip M, Dyrberg T. Progression to type 1 diabetes is associated with a change in the immunoglobulin isotype profile of autoantibodies to glutamic acid decarboxylase (GAD65). Childhood Diabetes in Finland Study Group. Clin Immunol 1999; 90(2): 276.
36. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice [see comments]. Nat Med 1996; 2(12): 1348.
37. Yilmaz S, Koskinen PK, Kallio E, Bruggeman CA, Hayry PJ, Lemstrom KB. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int 1996; 50(2): 526.
38. Warnock GL, Kneteman NM, Ryan EA, Rabinovitch A, Rajotte RV. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35(1): 89.